Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ Q4 2024 earnings at ($1.05) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($2.68) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at $0.00 EPS and FY2028 earnings at $1.62 EPS.

Separately, StockNews.com started coverage on shares of Minerva Neurosciences in a research note on Saturday, November 2nd. They set a “sell” rating on the stock.

Minerva Neurosciences Stock Up 1.0 %

NASDAQ:NERV opened at $2.34 on Wednesday. Minerva Neurosciences has a 52 week low of $2.26 and a 52 week high of $13.49. The firm has a 50 day moving average of $2.62 and a 200 day moving average of $2.79. The stock has a market capitalization of $16.38 million, a price-to-earnings ratio of -5.33 and a beta of 0.18.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.